| Autor: |
Zhao X; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Han B; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Tang W; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Ji S; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Wang L; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Huang J; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Hu Y; Department of Clinical Laboratory, The People's Hospital of Chizhou, Chizhou, China., Li J; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China. |
| Abstrakt: |
Chronic obstructive pulmonary disease (COPD) is a significant public health issue characterized by progressive and irreversible airflow limitation. The aim of this meta-analysis was to determine the association between changes in serum galectin-3 levels and COPD and to assess the relationship between serum galectin-3 levels and acute exacerbations of COPD (AECOPD). Relevant observational studies were retrieved from electronic databases, including PubMed, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI). A random-effects model was used to combine the data, incorporating the influence of between-study heterogeneity. Twelve case-control studies were included. The pooled results showed a significantly higher serum level of galectin-3 in patients with COPD compared to controls (standardized mean difference [SMD] 0.60; 95% confidence interval [CI] 0.40 - 0.80; P < 0.001; I2 = 68%). Further meta-analysis suggested higher levels of serum galectin-3 in patients with AECOPD compared to those with stable COPD (SMD 0.33; 95% CI 0.20 - 0.46; P < 0.001; I2 = 0%). Subgroup analyses according to the mean age of the participants, the proportion of males, and study quality scores did not significantly change the results (P for subgroup differences all > 0.05). In conclusion, patients with COPD were found to have higher serum levels of galectin-3, with levels further elevated in patients with AECOPD compared to those with stable COPD. |
